Edition:
United Kingdom

People: Editas Medicine Inc (EDIT.OQ)

EDIT.OQ on NASDAQ Stock Exchange Global Select Market

23.85USD
19 Jul 2019
Change (% chg)

$-0.82 (-3.32%)
Prev Close
$24.67
Open
$24.75
Day's High
$25.01
Day's Low
$23.67
Volume
227,281
Avg. Vol
241,752
52-wk High
$36.69
52-wk Low
$17.90

Bosley, Katrine 

Ms. Katrine S. Bosley is Director of the Company. She was President and Chief Executive Officer of the company. She has served as our President and Chief Executive Officer and a member of our board of directors since June 2014. Prior to joining Editas, Ms. Bosley was the Entrepreneur-in-Residence at The Broad Institute from September 2013 to May 2014. She served as Chief Executive Officer of Avila Therapeutics Inc., or Avila, a biotechnology company, from May 2009 to March 2012, when Avila was acquired by Celgene Corporation, or Celgene, a public biopharmaceutical company. Ms. Bosley served as President, Celgene Avilomics Research at Celgene from March 2012 to May 2012. Before Avila, she was Vice President, Strategic Operations at Adnexus, a Bristol-Myers Squibb Company and was Vice President, Business Development at Adnexus Therapeutics Inc., or Adnexus, a biotechnology company, before that. She joined Adnexus from Biogen Idec, Inc., a public biotechnology company, where she held roles in business development, commercial operations, and portfolio strategy in the United States and Europe. Earlier, she was part of the healthcare team at the venture firm Highland Capital Partners. Ms. Bosley currently serves as chairman of the board of directors of Genocea Biosciences, Inc., a public biotechnology company, and is a director of Galapagos NV, a public biotechnology company. She also serves on the board of directors of the Biotechnology Industry Organization, a not-for-profit organization. Ms. Bosley graduated from Cornell University with a B.A. in biological sciences. We believe that Ms. Bosley’s operational and historical experience with Editas gained from serving as our President and Chief Executive Officer and member of our board of directors, combined with her prior experiences in creating strategic and business development value and her network in the biopharmaceutical industry, qualifies her to serve as a member of our board of directors.

Basic Compensation

Total Annual Compensation, USD 821,800
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 7,167,580
Fiscal Year Total, USD 7,989,380

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

James Mullen

612,362

Cynthia Collins

479,814

Eric Ek

--

Vickesh Myer

2,455,740

Charles Albright

2,387,900

Katrine Bosley

7,989,380
As Of  31 Dec 2018